Optimized Dermal Delivery of Tetracaine for HSV-2 Lesion

This research will develop an effective topical medication for the treatment of genital herpes lesitetracaine as the active. ViroTex has found clinically that a topical cream containing 2% tetracainesulfate (the OTC product Viractin/¿) reduces the time to healing of herpes labialis lesions by 30%.permeation methodology, a topical tetracaine formulation having optimized drug delivery properties wConfirmation of earlier studies which indicated that tetracaine has antiviral activity will guide fotetracaine can inhibit herpes simplex virus type 2 replication, then maximum delivery across intacteffectively treat during the prodrome and papule state of lesion development. The combination of virdelivery characterization, and product characterization efforts will provide the information necessaInvestigational New Drug application. Based upon ViroTex's clinical results with Viractin¿, once apptopical product for genital herpes would be the only approved topical for the acute therapy of recurherpes. A year of treatment using the ViroTex topical is projected to cost the patient $40 comparedsuppressive Zorvirax therapy.